Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx to $590 from $545 and keeps a Buy rating on the shares. The firm’s raised target reflects continuous solid uptake of Vyvgart in gMG, ahead of its estimate, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- Argenx price target raised to $609 from $606 at Wells Fargo
- Next major rally in biotech likely not until end of 2024, says Capital One
- argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
- argenx announces closing of global offering
- Argenx price target raised to $575 from $545 at Piper Sandler